Improving the Risk Prediction of the 2015 ATA Recurrence Risk Stratification in Papillary Thyroid Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.New models integrating lymph node features and thyroglobulin levels improve predictions for papillary thyroid cancer (PTC) recurrence, aiding treatment decisions.
Area Of Science
- Endocrinology
- Oncology
- Medical Diagnostics
Background
- Papillary thyroid cancer (PTC) recurrence risk stratification is guided by American Thyroid Association guidelines.
- The impact of integrating additional prognostic factors on patient treatment decisions requires further investigation.
Purpose Of The Study
- To develop and validate predictive models for structural incomplete response (SIR) in PTC patients.
- To assess the clinical utility of these models compared to existing risk stratification.
Main Methods
- Two predictive models for SIR were developed using retrospective data from 2539 PTC patients.
- Model 1 included risk stratification and lymph node features; Model 2 added preablation stimulated thyroglobulin (s-Tg).
- Model performance was validated in a separate cohort of 746 patients using IDI, NRI, and decision curve analysis.
Main Results
- Both models demonstrated superior prediction of SIR compared to the standard risk stratification.
- Model 2 showed significant improvements in correct classification (event NRI = 53.54%) and clinical utility.
- Model 1 also showed improvement, though less pronounced in validation.
Conclusions
- Incorporating lymph node characteristics and s-Tg levels can enhance the accuracy and clinical utility of PTC risk stratification.
- These refined models offer potential for improved patient management and treatment decisions.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.